|
⚲
|
| Keyboard |
| Fairmount Funds Management LLC
✚
|
|
|---|---|
| CRD # | 284844 |
| SEC # | 801-116848 |
| CIK # | 0001802528 |
| AUM | 5,799.1 M (2026-03-31) |
| Employees | 30 (40% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 267-262-5300 |
| Address | 200 Barr Harbor Drive West Conshohocken, PA 19428 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Management Fee With respect to the Partnerships, Fairmount receives a management fee of 1.25% per annum based on the net asset value attributable to each Investor’s capital account. Management fees are paid quarterly in advance and are directly deducted from Investor accounts. The management fees are calculated independently by the Partnerships’ administrator and reviewed by Fairmount’s Chief Financial Officer. Fairmount may, in its discretion, waive, reduce, or rebate management fees with respect to certain Investors, including affiliates of the General Partners or Fairmount. No such waiver, reduction, or rebate will entitle any other Investor to similar treatment. Fairmount does not receive a management fee in connection with its management of Co- Invest III, Co-Invest IV, or Co-Invest V. Additional Fees and Expenses The Funds pay certain specific and customary expenses, including those detailed in their respective governing documents and agreements. These expenses typically include: (i) fees, costs, and expenses relating to attorneys, accountants, advisers, consultants (including sourcing, operating, research, industry expert, and other subject-matter consultants, as well as scientists and engineers), administrators, custodians, depositaries and paying agents, domiciliation agents, valuation experts, and data providers (including related systems, services, data management software, and information technology incorporated into the cost of obtaining such data); fees for temporary or long-term personnel or consultants engaged by Fairmount, including strategic advisors, senior advisors, and similar professionals who are not Fairmount employees but may be employees of portfolio companies or other entities in which a Fund invests); and fees relating to audit and certification, preparation and distribution of Investor reports, maintaining accounts, calculating net asset values, processing subscriptions, and Investor communications; (ii) fees payable to any placement agent engaged pursuant to local legal or regulatory requirements in connection with the offering of Fund interests outside the United States; (iii) brokerage commissions, prime brokerage fees, custodial expenses, other bank service fees and other investment costs, fees and expenses; (iv) expenses associated with auditing; (v) trade support services, including, pre- and post-trade support software and related services (including any and all fees, costs and expenses of any investment, books and records, portfolio compliance and reporting systems such as Bloomberg terminals, including consultant, software licensing, data management and recovery services fees and expenses) and data services providing price feeds, news feeds, security and company information and company fundamental data; (vi) risk analysis, risk reporting, and risk-related and consulting services provided by third parties; (vii) fees of providers of specialized data or analysis related to portfolio companies and the sector and asset classes in which a Fund has made or intends to make investments; (viii) research and technology expenses (including newswire, quotation services, publications, periodicals, subscriptions, database services, data processing related to research activities, and other information services); (ix) expenses associated with Investor communications and reporting (including annual information sessions or meetings and the maintenance of a website or other investor portal); (x) investment-related travel expenses (including transportation, lodging, internet access fees, international cellular charges, out-of-office meals, and other similar expenses); (xi) fees, costs, and expenses incurred in developing, bidding on, evaluating, investigating, negotiating, financing, refinancing, structuring, obtaining regulatory approvals for, purchasing, trading, clearing, settling, monitoring, maintaining custody of, holding and Fairmount Funds Management LLC Form ADV Part 2A disposing of investments, whether or not consummated, including due diligence, valuation, financing, legal, accounting, advisory, and consulting expenses, costs related to proxy contests (including professional fees); foreign exchange and other currency transaction costs; insurance, indemnity, litigation, investigation, and similar expenses; and any expenses related to short sales; (xii) expenses associated with withdrawals, redemptions, distributions, admissions, issuances and transfers of Fund interests (including preparation of any form transfer agreements); provided that the applicable transferor/transferee shall bear the material costs of any such transfer; (xiii) expenses associated with the acquisition, holding, monitoring, and disposition of investments, including brokerage, trading, custody, and hedging costs, commissions, and similar expenses incurred in connection with receiving, buying, selling, exchanging, trading, and otherwise dealing in securities and other Fund property (including expenses relating to spreads, short dividends, negative rebates, financing charges, currency hedging costs, and temporary investments); (xiv) interest and other expenses incurred in respect of a Fund’s borrowings, guarantees and other financing arrangements; (xv) costs and expenses of any lenders, investment banks and other financing sources; (xvi) fees, costs and expenses associated with a Fund’s financial statements, reports, notices, tax returns and Schedule K-1s (or similar schedules), including any related audits and the costs of preparing, translating, and distributing such materials (whether by a Fund, any affiliate or any service provider or agent engaged in connection therewith); (xvii) out-of-pocket fees, costs, and expenses incurred in connection with a Fund’s legal, tax, and regulatory compliance with applicable U.S. federal, state, local, non-U.S., or other laws or regulations, ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7: Types of Clients As previously described in Item 4, Fairmount’s clients are the Funds. With respect to the Funds, any initial and additional subscription minimums are described in the relevant offering documents and may be waived or modified by Fairmount or its affiliates. The Funds are open only to certain financially sophisticated investors who meet eligibility criteria. Fairmount Funds Management LLC Form ADV Part 2A |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Galecto Inc | 225.7 | ||
| Magenta Therapeutics Inc | 212.9 | ||
| UNUM Therapeutics Inc | 211.8 | ||
| Aeglea Biotherapeutics Inc | 202.7 | ||
| ARCA Biopharma Inc | 181.7 | ||
| Signal Genetics Inc | 76.6 | ||
| Imara Inc | 72.7 | ||
| Aerovate Therapeutics Inc | 64.0 | ||
| Glycomimetics Inc | 50.5 | ||
| Zenas Biopharma Inc | 46.1 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Fairmount Healthcare Co-Invest V LP | [2026-02-10] | 80.3 M | |
| Filed 2025-11-05 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest IV LP | [2025-02-20] | 41.6 M | |
| Filed 2024-10-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest III LP | [2024-08-15] | 78.6 M | |
| Filed 2024-03-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest II LP | [2023-11-15] | 15.2 M | 24.9 M |
| Offered $15,173,000 · Filed 2023-08-21 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount Healthcare Co-Invest LP | [2023-08-18] | 25.0 M | 38.7 M |
| Offered $25,000,000 · Filed 2023-06-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose | ||||
| PE | Fairmount SPV I LLC | 2022-03-31 | 1.6 M | |
| PE | Fairmount SPV III LLC | 2020-04-17 | 0.6 M | |
| HF | Fairmount Healthcare Fund II LP | [2019-05-24] | 28.0 M | 5,598.6 M |
| Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Fairmount SPV II LLC | 2019-05-24 | 0.4 M | |
| HF | Fairmount Healthcare Fund LP | [2018-02-13] | 3.6 M | 111.0 M |
| Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 5.8 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 5.8 |
| By Discretionary | ||
| Discretionary | 4 | 5.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 5.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.8 | |
| United States Persons | 3.0 | |
| Total | 4 | 5.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Tomas Kiselak | Executive Officer | 25 | 2 | |
| Peter Harwin | Executive Officer | 22 | 2 | |
| Fairmount Funds Management LLC | Executive Officer | 8 | 2 | |
| Investment Manager Fairmount Funds Management LLC | Promoter | 2 | 1 | |
| General Partner Fairmount Healthcare Fund GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001802528] | |
| 3 | [0001802528] | |
| 4 | [0001802528] | |
| SC 13D | [0001802528] | |
| SC 13G | [0001802528] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300KMPFHUFJ6T6Y84 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Conversion | 7,000,000 | ||
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Sell | 7,000,000 | $34.66 | 242,620,000 |
|
Cogent Biosciences Inc COGT
Series A Convertible Preferred Stock · derivative
|
2026-03-31 | Conversion | 28,000 | $0.00 | |
|
Damora Therapeutics Inc DMRA
Stock Option (right to buy) · derivative
|
2026-03-23 | Grant | 37,313 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 5,809,000 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 5,809 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 2,904 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 2,904,000 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Common Stock
|
2026-01-22 | Sell | 1,750,000 | $76.30 | 133,525,000 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-01-22 | Sell | 3,500,000 | $36.40 | 127,400,000 |
|
Crescent Biopharma Inc CBIO
Ordinary Shares
|
2025-12-04 | Buy | 1,360,000 | $13.41 | 18,237,600 |
|
Crescent Biopharma Inc CBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-12-04 | Buy | 131,434 | $13.41 | 1,762,530 |
|
Miragen Therapeutics Inc VRDN
Common Stock
|
2025-10-23 | Buy | 454,545 | $22.00 | 9,999,990 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2025-10-07 | Buy | 316,219 | $19.00 | 6,008,161 |
|
Jade Biosciences Inc JBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-10-06 | Grant | 855,047 | $9.14 | 7,815,130 |
|
Jade Biosciences Inc JBIO
Common Stock
|
2025-10-06 | Grant | 1,333,126 | $9.14 | 12,184,772 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2025-07-10 | Buy | 2,777,777 | $9.00 | 24,999,993 |
|
Crescent Biopharma Inc CBIO
Stock Option (Right to Buy) · derivative
|
2025-06-23 | Grant | 9,023 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
| showing 20 of 110 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
PennantPark Investment Advisers LLC
✚
|
FL | 6,155.9 M |
|
Polen Capital Credit LLC
✚
|
MA | 6,129.5 M |
|
JC Flowers & Co LLC
✚
|
NY | 6,010.1 M |
|
HG VORA Capital Management LLC
✚
|
NY | 5,872.6 M |
|
Torchlight Investors LLC
✚
|
NY | 5,843.9 M |
|
Sun Capital Advisors LP
✚
|
FL | 5,843.3 M |
|
Axium Infrastructure US Inc
✚
|
NY | 5,830.4 M |
|
Saluda Grade Asset Management LLC
✚
|
NY | 5,826.7 M |
|
Dynamic Beta Investments LLC
✚
|
CT | 5,674.3 M |
|
Lime Rock Management LP
✚
|
CT | 5,478.5 M |